{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-018800","form_type":"8-K","ticker":"PDSB","cik":"0001472091","company_name":"PDS Biotechnology Corp","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.401935+00:00","generated_at":"2026-05-21T08:23:15.527771+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"PDS Biotech Q1 net loss $8.5M; Phase 3 VERSATILE-003 trial underway","bullets":["Net loss of $8.5M ($0.21 per share) in Q1 2025 vs $10.6M ($0.30) in Q1 2024; R&D expenses fell to $5.8M.","Cash and equivalents $40M as of March 31, 2025; includes $11M from Feb 2025 registered direct offering with warrants for up to $11M more.","VERSATILE-003 Phase 3 trial initiated for Versamune HPV + pembrolizumab in HPV16-positive HNSCC; targets ~350 patients with 2:1 randomization.","FDA cleared IND for Versamune MUC1 + PDS01ADC in metastatic colorectal cancer; NCI to lead Phase 1/2 under CRADA.","Three Versamune HPV abstracts selected for presentation at 2025 ASCO Annual Meeting (May 30-June 3)."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-018800","json":"https://secwatch.observer/filing/0001140361-25-018800.json","markdown":"https://secwatch.observer/filing/0001140361-25-018800.md","text":"https://secwatch.observer/filing/0001140361-25-018800.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472091/000114036125018800/0001140361-25-018800-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472091/000114036125018800/ef20048917_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T08:23:15.527771+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}